ZELLUNA IMMUNOTHERAPY
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients. Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudern... ack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development. We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products.
ZELLUNA IMMUNOTHERAPY
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.zelluna.com
Total Employee:
11+
Status:
Active
Contact:
47 22 84 00 80
Email Addresses:
[email protected]
Total Funding:
7.5 M EUR
Technology used in webpage:
Euro CrUX Dataset CrUX Top 10m
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
BAV Institut
BAV Institut is a testing laboratory for food, cosmetics, and pharmaceutical companies.
Built by Doctors
Built by Doctors specializes in developing medical support guides for pharmaceutical companies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Takeda Ventures
Takeda Ventures investment in Venture Round - Zelluna Immunotherapy
Birk Venture
Birk Venture investment in Seed Round - Zelluna Immunotherapy
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-19 | Zelluna Immunotherapy appoints new chief executive |
Official Site Inspections
http://www.zelluna.com Semrush global rank: 11.53 M Semrush visits lastest month: 156
- Host name: 68.183.241.158
- IP address: 68.183.241.158
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Zelluna Immunotherapy"
About Zelluna
The Zelluna Academy was established to represent the various programs and activities intended to support continuous learning and development for individuals and teams across the organisation. Zelluna Immunotherapy AS was …See details»
Zelluna Immunotherapy - Crunchbase Company Profile & Funding
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. ... (Norwegian Centre of …See details»
Management - Zelluna
Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit and pipeline as well as helping to secure up to $40M of funding for the …See details»
Zelluna Reaches Major Milestone with Manufacturing…
1 day ago Zelluna has partnered with Catalent, a leading global contract development and manufacturing organization (CDMO), for process development and manufacturing. Catalent …See details»
Zelluna Immunotherapy - Products, Competitors, Financials, …
Zelluna Immunotherapy focuses on allogeneic T cell receptor (TCR) guided natural killer (NK) cell therapies for the treatment of solid cancers within the biopharmaceutical sector. ... Zelluna has …See details»
Zelluna Immunotherapy - Funding, Financials, Valuation & Investors
Zelluna Immunotherapy is registered under the ticker OSE:ZLNA . Their stock opened with NOK2.29 in its Mar 3, 2025 IPO. Stock Symbol OSE:ZLNA ; Valuation at IPO NOK463.2M; …See details»
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on …
Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims …See details»
Zelluna Immunotherapy - BIO International Convention …
Jun 5, 2023 Zelluna's pipeline consists of programs targeting TCR antigens shown clinically to be viable targets for a broad range of solid cancers (e.g MAGE-A4 and PRAME). Zelluna is uniquely positioned in the field, with broad …See details»
Zelluna ASA [ZLNA]: The first ever cell therapy company ... - 台湾新闻
Mar 3, 2025 Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The …See details»
Zelluna ASA, ZLNA:OSL profile - FT.com - Financial Times
3 days ago Zelluna ASA, formerly Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company develops cell therapies for the …See details»
Zelluna Reaches Major Milestone with Manufacturing Process
3 days ago Zelluna has partnered with Catalent, a leading global contract development and manufacturing organization (CDMO), for process development and manufacturing. Catalent …See details»
Contact us - Zelluna
Zelluna ASA E-mail: [email protected] [email protected] [email protected] [email protected]. Phone number: +47 413 80 080 Ullernchausséen 64 0379 Oslo Norway View in Google Maps. …See details»
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on …
Mar 3, 2025 Namir Hassan, CEO, Zelluna ASA Email: [email protected] Phone: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASA Email: [email protected] Phone: …See details»
Zelluna lists on Euronext
Mar 4, 2025 Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The …See details»
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on …
Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today …See details»
Zelluna - EU-Startups
Zelluna’s core asset is a wide range of TCRsisolated from patients who exhibited long-term survival following inclusion in peptide-based cancer vaccine trials initiated by Prof Gustav …See details»
Zelluna Reaches Major Milestone with Manufacturing Process …
4 days ago Zelluna has partnered with Catalent, a leading global contract development and manufacturing organization (CDMO), for process development and manufacturing. Catalent …See details»
Zelluna Reaches Major Milestone with Manufacturing Process …
Zelluna has partnered with Catalent, a leading global contract development and manufacturing organization (CDMO), for process development and manufacturing. ... Emilie Gauthy, Head of …See details»
Zelluna Reaches Major Milestone with Manufacturing Process …
3 days ago Zelluna has partnered with Catalent, a leading global contract development and manufacturing organization (CDMO), for process development and manufacturing. Catalent …See details»
Zelluna ASA [ZLNA]: The first ever cell therapy company to
Mar 3, 2025 Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The …See details»